{Reference Type}: Journal Article
{Title}: Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review.
{Author}: Han Z;Liang J;Li Y;He J;
{Journal}: Biomed Res Int
{Volume}: 2019
{Issue}: 0
{Year}: 2019
暂无{DOI}: 10.1155/2019/1212369
{Abstract}: B-cell lymphoma 2 (Bcl-2) is a regulator protein involved in apoptosis. In the past few decades, this protein has been demonstrated to have high efficacy in cancer therapy, and several approaches targeting Bcl-2 have been tested clinically (e.g., oblimersen, ABT-737, ABT-263, obatoclax mesylate, and AT-101). This review reports potential Bcl-2 inhibitors according to current information on their underlying mechanism and the results of clinical trials. In addition, the function and mechanisms of other potentially valuable Bcl-2 inhibitors that did not show efficacy in clinical studies are also discussed. This summary of the development of Bcl-2 inhibitors provides worthwhile viewpoints on the use of biomedical approaches in future cancer therapy.